Reprogramming of IL-12 secretion in the PDCD1 locus improves the anti-tumor activity of NY-ESO-1 TCR-T cells.

Kim, Segi; Park, Cho I; Lee, Sunhwa; Choi, Hyeong Ryeol; Kim, Chan Hyuk

Kim, Segi; Park, Cho I; Lee, Sunhwa; Choi, Hyeong Ryeol; Kim, Chan Hyuk.

Afiliação

Kim S; Department of Biological Sciences, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea.
Park CI; Department of Biological Sciences, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea.
Lee S; Department of Biological Sciences, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea.
Choi HR; Department of Biological Sciences, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea.
Kim CH; Department of Biological Sciences, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea.

Front Immunol ; 14: 1062365, 2023.

Article em En | MEDLINE | ID: mdl-36793716

Assuntos

Neoplasias Esofágicas; Carcinoma de Células Escamosas do Esôfago; Humanos; Camundongos; Animais; Receptor de Morte Celular Programada 1/genética; Receptor de Morte Celular Programada 1/metabolismo; Neoplasias Esofágicas/metabolismo; Linfócitos T; Citocinas/metabolismo; Receptores de Antígenos de Linfócitos T/genética; Receptores de Antígenos de Linfócitos T/metabolismo; Interleucina-12/genética; Interleucina-12/metabolismo

Palavras-chave

CRISPR/Cas9; NY-ESO-1; PD-1; TCR-T; immunotherapy; interleukin-12

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Esofágicas / Carcinoma de Células Escamosas do Esôfago Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google